Endo Investors Seek Class Cert. In Opioid Stock-Drop Suit

By Reenat Sinay (May 23, 2019, 2:58 PM EDT) -- Endo International PLC investors have asked a Pennsylvania federal court to grant them class certification in their suit claiming the pharmaceutical company knowingly misrepresented the safety of its opioid drug Opana, leading to a significant stock drop when it was forcibly removed from the market....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!